RCEL: Operational discipline and portfolio expansion drive growth, with cash flow breakeven targeted for Q4 2026Quartr·Sep 16 at 06:21 PMRCEL+6.83%
Avita Medical management attends Morgan Stanley Global Healthcare Conference fireside chatPUBT·Sep 2 at 08:11 PMRCEL+6.83%MS-3.55%
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. AllograftMarket Beat·Aug 19 at 12:02 PMRCEL+6.83%
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes | RCEL Stock NewsStockTitan·Aug 18 at 03:45 AMRCEL+6.83%
Avita Medical amends PermeaDerm deal with Stedical, pays USD 500.000 for right to expand exclusive territoryPUBT·Aug 11 at 08:35 PMRCEL+6.83%
AVITA Medical to Host Investor Webinar Briefing | RCEL Stock NewsStockTitan·Aug 9 at 02:00 PMRCEL+6.83%
Biotech and MedTech Sector Signals Divergent Paths Post-EarningsGlobal Report·Aug 9 at 09:12 AMRAIN+8.46%GENB+1.47%
The Biotech Divide of 2026: Commercial Titans vs. AI HopefulsGlobal Report·Aug 8 at 09:21 AMRAIN+8.46%GENB+1.47%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Aug 7 at 05:05 PMCVRX+1.68%EMBC+2.64%
